Novo Nordisk Raises 2026 Outlook Amid Strong Demand for Obesity Drugs

Despite softer first-quarter results due to pricing pressure, Novo Nordisk raised its full-year guidance in 2026 citing strong demand for obesity and diabetes treatments. The company expects a narrower sales contraction than previously anticipated.

By Fiona Craig Wed, May 6, 2026 at 1:35 PM GMT+3 2 min read · Yahoo Finance · May 6, 2026, 10:35 UTC

Novo Nordisk Raises 2026 Outlook Amid Strong Demand for Obesity Drugs

Tickers: $MS $NVO

Topics: GLP-1 drugs obesity treatments pharmaceuticals Wegovy

Read the full article at Yahoo Finance

More World news

CNBC Select Names Accredited Debt Relief Best for Debt Resources PR Newswire · November 12, 2026, 19:25 UTC
CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Tetra Tech Forecasts FY 2027 Revenue Between $4.425B and $4.625B Amid Backlog Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Donald Trump Jr. Steps Down from Kalshi Advisory Role Due to Conflict of Interest CNBC · November 12, 2026, 19:14 UTC
Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC